Teniente-Valente R, Solorio-Meza S, Hernández-González M, Delgado-Sánchez AC, Vargas-Ramírez L, Sánchez-López M, Medina-Torres ÓS

Language: Spanish
References: 28
Page: 130-134
PDF size: 82.08 Kb.

ABSTRACT

In the Acute ST-Elevation Myocardial Infarction (STEMI) the reperfusion therapy (RT) diminishes the morbidity and mortality. Nevertheless, a proportion of the patients with this diagnosis does not receive the benefit of this treatment. Objective: To know the number of patients with STEMI who underwent RT and the opportunity whereupon this treatment was applied. Material y methods: The data base of the patients who entered the Unit of Cardiovascular Intensive Care of our hospital from January 2005 to June 2006 with the STEMI diagnosis were reviewed. The type of treatment and opportunity of the same were evaluated. Results: A total of 144 patients, between 28 and 94 years (61.1 ± 11.5 years) were enrolled. 72.2% (104) were men. 59.7% (86) underwent fibrinolysis therapy, 5.5% (8) underwent percutaneous coronary intervention (PCI) and 34.7% (50) did not receive reperfusion therapy. 32.5% (28) underwent fibrinolysis after 6 hours. In 84.8% (73) of the cases use rTPA and 15.2% (13) streptokinase. Conclusions: 34.7% of the patients with STEMI did not receive reperfusion therapy. Of the patients who underwent fibrinolysis, few were in the recommended time. It is necessary to implement strategies that allow to increase the proportion of patients with STEMI that receive the benefit of the reperfusion therapy as well as to improve the time in which it is applied.

REFERENCES

1. Rosas-Peralta M, Attie F. Enfermedad cardiovascular. Primera causa de muerte en adultos de México y el mundo. Arch Cardiol Méx 2007; 77: 91-93.

2. Antman EM, Braunwald E. ST-segment elevation acute myocardial infarction in Braunwald´s Heart Disease: A Textbook of Cardiovascular Medicine, 7ª edition 2006, vol 11, Elsevier Saunders. Philadelphia.

3. Martínez-Sánchez CR, Arias-Mendoza MA, Martínez-Reding García JO, Rojas-Velazco G. Capítulo 7 Terapia de reperfusión en: Síndromes isquémicos coronarios agudos. Intersistemas SA de CV. México, 2007: 121-172.

4. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. (Gruppo Italiano per lo Studio della Streptochinasi nell´ Infarto miocardico). GISSI Study. Lancet 1986; 1: 397-402.

5. Wilcox RG, von der Lippe G, Olsson GC, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988; 2: 525-530.

6. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS Study. AIMS Trial Study Group. Lancet 1990; 335: 427-431.

7. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 ( Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2: 349-360.

8. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1,000 patients. Fibrinolytic Therapy Trialists´(FTT) Collaborative Group. Lancet 1994; 343: 311-322.

9. Yusuf S, Sleight P, Held P, McMahon S. Routine medical management of acute myocardial infarction. Lessons from overviews of recent randomized controlled trials. Circulation 1990; 82: 117-134.

10. Grines CL, Browne KF, Marco J et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993; 328: 673-679.

11. Zijlstra F, de Boer MJ, Hoornje JC et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993; 328: 680-684.

12. Gibbons RJ, Holmes DR, Reeder GS, et al. for the Mayo Coronary Care Unit and Catheterization Laboratory Groups. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993; 328: 685-691.

13. Ribeiro EE, Silva LA, Carneiro R et al. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 1993; 22: 376-380.

14. GUSTO IIb. A Clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336: 1621-1628.

15. Schomig A, Kastrati A, Dirschinger J et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 2000; 343: 385-391.

16. LeMay MR, Labinaz M, Davies RF et al. Stenting versus thrombolysis in acute myocardial infarction trial (STAT). J Am Coll Cardiol 2001; 37: 985-991.

17. Kastrati A, Mehilli J, Dirshinger J et al. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomized trial. Lancet 2002; 359: 920-925.

18. Weaver WD, Simes J, Betriu A et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction. JAMA 1997; 278: 2093-2098.

19. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003; 361: 13-20.

20. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholtz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fusater V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK. ACC/AHA Guidelines for the Management of patients with ST-Elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on practice Guidelines (Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction. Circulation 2004; 110: 1-49.

21. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, Julian D, Lengyei M, Neumann FJ, Ruzyllon W, Thygeson C, Underwood SR, Vahanian A, Verheugt FW, Wijns W. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24: 28-66.

22. Guías Clínicas para el manejo del Infarto Agudo del Miocardio con elevación del segmento ST: Grupo de trabajo de la Sociedad Mexicana de Cardiología y Asociación Nacional de Cardiólogos de México. Arch Cardiol Mex 2006; 76 Supl 3: 11-120.

23. European secondary prevention study group. Translation of trial into practice: a European population-based study of the use of thrombolysis for acute myocardial infarction. Lancet 1996; 347: 1203-1207.

24. Gibson CM. NRMI and current treatment patterns for ST-elevation myocardial infarction. Am Heart J 2004; 148: S29-33.

25. Eagle KA, Goodman SD, Avezum A, Budaj A, Sullivan CM, López-Sendón J, for the GRACE investigators. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002; 359: 373-377.

26. Eagle KA, Nallamothu BK, Mehtaa RH, Granger CB, Steg PG, Van de Werf F, López-Sendón J, Goodman SG, Quill A, Fox KAA, for the Global Registry of Acute Coronary Events (GRACE) Investigators. Eur Heart J 2008; 29: 609-617.

27. Lupi-Herrera E et al. El Registro Nacional de los Síndromes Isquémicos Coronarios Agudos (RENASICA). Sociedad Mexicana de Cardiología. Arch Cardiol Mex 2002; 72: S45-S64.

28. García-Castillo A, Sánchez CJ, Martínez-Bermúdez P, Azpiri-López R, Autrey-Caballero A, Martínez-Sánchez C, Ramos-Corrales MA, Llamas G, Martínez-Sánchez J, Treviño AJ. RENASICA II. Arch Cardiol Mex 2005: 75: S6-S19.